Vancouver-based Chinese biotechnology firm Virogin Biotech has pocketed $62 million in a Series C round co-led by Chinese alternative management firm CDH Investments and CMG-SDIC Fund, a joint fund of state-owned SDIC Fund Management and China Merchants Capital.
The round also saw participation from Seoul-based Korea Investment Partners (KIP), healthcare-focused Panlin Capital, Linden Asset, Xiaoxi Holdings, and Peking University Alumni (Canada), CDH announced on Monday.
